ORLANDO, FL, July 26, 2016 — Hemophilia patients can be managed with less factor VIII without affecting outcomes and saving significant costs, suggests a study being presented at the World Federation of Hemophilia 2016 World Congress meeting today in Orlando.

此项 Option Care 研究包括接受第八因子家庭输液治疗的 77 名 A 型血友病患者。他们每周接受了平均 102 单位的第八因子，与全美平均的每周 108 单位相比，相当于每名患者每年可节省 21,165 美元的费用。这些患者的年出血率 (ABR)（即患者一年出现的出血次数）为 1.7 次，少于最近一项关于血友病治疗策略的回顾性研究中所称的平均 ABR 2 到 5 次。

“通过与处方医师合作以密切监测出血情况，并在临床上适当优化治疗剂量方面开展协作，Option Care 对第八因子的利用率低于平均水平，却有着卓越的成效，”Option Care 的出血性疾病项目的全国项目主任 Joan Couden 说道。“我们的研究成果显示，我们可以为包括 Medicare、Medicaid 以及管理式医疗保险公司在内的支付方节省大量的成本，同时又不会对年出血率产生负面影响。”

血友病患者缺少控制出血的凝血蛋白。治疗包括输注第八因子，这有助于血液凝块和停止出血。许多该病患者每周要接受三至四次的第八因子注射，以预防或减少出血。治疗成功率通过评定年出血率 (ABR) 进行评估。出血次数越少，治疗就越成功。

除了提供第八因子来预防出血，当出血确实发生时，务必尽快治疗出血，以帮助减少关节、肌肉和器官的疼痛和损伤。当快速治疗出血时，用来止血的血液制品需求量较少，Couden 如是说。

她说，目前，凝血因子是按单位来付款的，这就为提供更多产品带来了经济诱因，尽管这并不能转化为更好的护理。她指出，支付方可能需要考虑不同的赔付策略，以减少配发较多第八因子的诱因。

患者和医疗保健提供者的支持与教育是 Option Care 的出血性疾病 (BD) 家庭输液+项目的关键组成部分，该项目遵循了多学科团队的护理方法。项目提供由 BD 认证的专科护士和药剂师负责的个性化临床护理。每位患者都会收到特定疾病的定制护理计划，该计划专注于实现患者及其护理团队的需求。我们会向医师和医疗保健服务提供者提供每位患者状态的详细报告，包括出血的部位和严重程度、患者的疗效和依从性等。

关于 Option Care

Option Care Enterprises, Inc. (Option Care) is one of the nation’s largest and most trusted providers of home and alternate treatment site infusion services. An industry leader, the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide home infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions. Learn more at www.OptionCare.com.

# # #

DEERFIELD, Ill. — Option Care Enterprises, Inc., an independent infusion services company, has been selected as a contracted provider of Coagadex ® (Coagulation Factor X Human), the first and only treatment approved by the U.S. Food and Drug Administration specifically for hereditary factor X deficiency, a rare and serious bleeding disorder. Coagadex is manufactured by Bio Products Laboratory, Ltd.

Coagadex is an injectable medication provided to patients with hereditary factor X deficiency for the controlling of bleeding episodes or management of surgery-related bleeding. An inherited disorder that prevents the blood from clotting as it should, factor X deficiency currently affects approximately 300 to 600 men and women in the United States. Previously, no specific coagulation factor replacement therapy was available for patients with this condition.

One of the nation’s largest providers of home and alternate treatment site infusion services — including for bleeding disorder management — Option Care was chosen to provide and support the administration of Coagadex due to its ability to provide high-quality clinical support to patients undergoing treatment for complex conditions. The company has the ability to serve patients with hereditary factor X deficiency wherever they are through its 92 infusion pharmacies and 110 alternate treatment sites nationwide.

“We’re honored to work with the bleeding disorders community and are committed to providing these patients the highest quality care, “ said Joan Couden, bleeding disorder program director for Option Care. “Our specially trained infusion nurses and pharmacists have a wealth of experience in caring for patients with rare and complex bleeding disorders. By safely providing therapy, monitoring their progress and working closely with their physicians, our team ensures our patients experience optimal outcomes. “

Coagadex was approved by the FDA on Oct. 20 for on-demand treatment and control of bleeding episodes and for management of bleeding before, during and after surgery in patients with mild hereditary factor X deficiency. It was granted orphan product designation, which is given to promote the development of drugs intended to treat rare diseases. The approval of the purified factor X concentrate increases therapy options for patients with hereditary factor X deficiency, with the goal of replacing their missing X factor without adding other clotting factors they don’t need.

“Option Care’s experience providing patients with access to high-quality, high-touch healthcare services for complex conditions has allowed it to develop programs with biopharmaceutical manufacturers to manage and advance patient care, “ said Matthew Deans, vice president of business development for Option Care. “These manufacturers view Option Care as a partner of choice because of our proven track record of effectively managing patient and physician relationships to help ensure successful outcomes for patients on therapies including those where healthcare professional administration is not just preferred, but required. “

关于 Option Care

Option Care Enterprises, Inc.（前身为 Walgreens Infusion Services）由经过专门培训的输液护士、药剂师和营养师提供临床护理，医治各式急性、慢性和罕见疾病的患者。作为全美最大的家庭和备选医疗站点输液服务提供者之一，Option Care 在美国各地拥有 92 家输液药房和 110 个备选医疗站点。有关详情请访问 www.OptionCare.com。

# # #

媒体联系人信息

Option Care
Lauren Kotarski
312-558-1770
LKotarski@pcipr.com